MAR 11, 2016 1:12 PM PST

Common Kidney Cancer Drugs Don't Improve Patient Survival

WRITTEN BY: Xuan Pham

To fight cancer, doctors often resort to aggressive treatments that include surgery followed by secondary chemotherapies. This tactic works for many cancer types, but unfortunately not for kidney cancer. In a large, random, double-blind study, researchers at the University of Pennsylvania found that two commonly used anti-cancer drugs, sorafenib and sunitinib, were no more effective than placebos at preventing kidney cancer recurrence. The study has implications for drugs that should and shouldn’t be in a patient’s adjuvant therapy following surgery.
 

Image credit: Pixabay.com

Kidney cancer accounts for nearly 4% of all new cancer cases every year. Although the cancer has a relatively modestly high five-year survival rate at 73.2%, the disease still claimed over 14,000 lives in 2015 alone. Typically, surgery to remove the cancerous growth in the kidneys is the best initial treatment. However, the surgery alone is ineffective at preventing relapse in patients. As such, doctors often prescribe adjuvant therapies, which are secondary anti-cancer treatments to maximize the effectiveness of the surgery.
 
In the case of kidney cancer, sorafenib (Nexavar, Bayer/Onyx Pharmaceuticals) and sunitinib (Sutent, Pfizer) are widely used in the hope of improving patient survival after surgery. The drugs are anti-angiogenic agents that inhibit the kinase known as vascular endothelial growth factor (VEGF). By inhibiting VEGF, the drugs block the growth of blood vessels that enable cancer to survive and proliferate.
 
While the drugs’ actions seem to fit with the goal of stopping the cancer, researchers found no difference in patient survival when treated with these drugs compared to when treated with placebos.
 
The double-blind, placebo-controlled, phase 3 trial included 1,943 patients from 226 study centers in the US and Canada. All patients were diagnosed with high-grade kidney cancer at stage T1b (tumor is larger than 4 cm but not larger than 7 cm across and is only in the kidney), and had undergone surgery to remove the non-metastatic cancer. They were then randomly assigned to the sorafenib group, the sunitinib group, or the placebo group for 54 weeks.
 
In analyzing survival rates between the three treatments after surgery, researchers found no significant differences: Median disease-free survival was 5.8 years with sunitinib, 6.1 years with sorafenib, and 6.6 years with placebo.
 
While the drugs did not reduce kidney cancer recurrence, the researchers found the drugs “did not appear to make the outcome of patients receiving them any worse,” said Naomi Haas, first study author.
 
The findings are similar to other trials that reported the ineffectiveness of the anti-cancer drug bevacizumab in the adjuvant setting in breast and metastatic colorectal cancers.
 
While these results seem discouraging, studies like these are important as they help doctors identify which drugs will and will not be effective for the patients. After all, given the toxicity and side-effects of chemotherapies, it is equally important to understand which drugs to not take, as well as which to take. Studies like this also give insight into how cancer recurrence occurs, and specific to kidney cancer, the pathways may not involve VEGF at all. 
 


Additional source: EurekAlert!

About the Author
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 30, 2022
Health & Medicine
Large-Scale Study Suggests Link Between Temporary Menstrual Changes and Covid-19 Vaccine
JUL 30, 2022
Large-Scale Study Suggests Link Between Temporary Menstrual Changes and Covid-19 Vaccine
The most comprehensive analysis of menstrual changes following a Covid-19 vaccination has revealed that its recipients e ...
AUG 07, 2022
Microbiology
Paralytic Polio Case ID'ed in New York & Health Officials are Concerned
AUG 07, 2022
Paralytic Polio Case ID'ed in New York & Health Officials are Concerned
Polio is a disease caused by the poliovirus. Polio can cause flu-like symptoms like nausea, headache, fever, and sore th ...
AUG 15, 2022
Clinical & Molecular DX
Revolutionizing Healthcare Testing: 1health Unveils Next Generation Diagnostic Platform that Enables Precision Medicine at Scale
AUG 15, 2022
Revolutionizing Healthcare Testing: 1health Unveils Next Generation Diagnostic Platform that Enables Precision Medicine at Scale
SAN FRANCISCO, CA - July 11, 2022: 1health.io Inc. (“1health”), an industry-leading software company that em ...
AUG 25, 2022
Drug Discovery & Development
Seasonal Flu Could Get Knockout Punch from Antiviral Drugs and Antibody Therapy Combo
AUG 25, 2022
Seasonal Flu Could Get Knockout Punch from Antiviral Drugs and Antibody Therapy Combo
In a recent study published in Cell Reports Medicine, a team of researchers from McMaster University in Ontario, Canada ...
AUG 25, 2022
Cancer
Nearly Half of Global Cancer Deaths Attributed to Behavioral Risk Factors
AUG 25, 2022
Nearly Half of Global Cancer Deaths Attributed to Behavioral Risk Factors
Cancer is a broad description of various related diseases resulting from abnormal and excessive cell growth.  While ...
SEP 28, 2022
Health & Medicine
After COVID-19 Infection, Risk of Blood Clots Could Remain for a Year
SEP 28, 2022
After COVID-19 Infection, Risk of Blood Clots Could Remain for a Year
Blood clots are a known risk from a COVID-19 infection. Blood clots are clumps of blood that naturally form to help the ...
Loading Comments...